GeneDx
GeneDx runs the leading rare-disease exome and genome sequencing lab in the US.
On the record
Checkpoint: Q2 2026 earnings and progress toward the promised Q3 2026 return to profitability
The call
GeneDx still leads rare-disease sequencing by a wide margin, but a guidance cut, a stock crash, and Natera's new test have put its financial story under real strain.
GeneDx runs the largest genetic testing service for rare diseases, sequencing patient DNA to find disease-causing mutations. The company has built up a huge library of over one million sequenced genomes and strong relationships with insurance companies and doctors over 25 years, which makes it hard for competitors to copy quickly. However, insurance companies are paying less for whole-genome tests than for the simpler exome tests GeneDx relied on, which is shrinking profits even as more patients get tested. Natera just launched a competing test called Zenith in 2026, and GeneDx's stock crashed 49% in May 2026 after missing financial targets, raising questions about whether the company can turn around its money-losing operations.
Why
01
AI pressure: None apparent. GeneDx bet on AI itself with Fabric Genomics, then wrote off 94% of that bet, so AI is feeding costs, not yet eating share. Could AI do the core job? Unlikely.
02
Bigger players: Natera. Natera shipped its Zenith rare-disease test in 2026 with its own MyOme genomic dataset, aiming straight at GeneDx's core market. Could a giant copy it? Probably.
03
What protects it. Over 1 million sequenced exomes, 2.5 million tests, and 25 years of payer and clinician relationships that are hard to rebuild fast.
What would change this call
GeneDx Q2/Q3 2026 earnings show whether revised guidance of $475-490M holds. Confirms whether the May 2026 guidance cut stabilizes or deteriorates further.
Natera reports Zenith test volume or revenue traction in 2026 quarterly filings. Would show whether Natera is converting its dataset into real share gains against GeneDx.
Outcome of securities class-action lead-plaintiff process after August 3, 2026 deadline. Indicates financial and reputational exposure from the guidance-cut litigation.
Natera reports Zenith test volume or revenue traction in 2026 quarterly filings. Would show whether Natera is converting its dataset into real share gains against GeneDx.
Outcome of securities class-action lead-plaintiff process after August 3, 2026 deadline. Indicates financial and reputational exposure from the guidance-cut litigation.
Key numbers
- Stock fell ~49% in one day after guidance cut
- 2026 revenue guidance cut from $540-555M to $475-490M
- Q1 2026 revenue $102.3M, up 17% YoY
Named risks
- Pending securities class action over May 2026 guidance cut, lead-plaintiff deadline Aug 3, 2026.
- Unfavorable genome-versus-exome reimbursement mix pressuring margins and revenue guidance.
- Natera's 2026 Zenith test entry into rare-disease genomic testing threatens GeneDx's ~80% share.
- Fabric Genomics AI acquisition wrote off ~94% of cash paid, unproven monetization path.
- Continued GAAP losses ($63.3M in Q1 2026) despite strong volume growth.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Natera | gaining on | Shipped rare-disease genomic test Zenith with MyOme, presented at ACMG 2026; ~$21B market cap vs GeneDx turmoil |
| Invitae | gaining on | Invitae filed bankruptcy Feb 2024, sold for under $300M from ~$12B valuation, ceding ground to GeneDx |
| Labcorp/Quest Diagnostics | contesting | Large distribution and payer contracts but reportedly lack GeneDx's rare-disease bioinformatics depth, per 2026 trade commentary |
| Fulgent Genetics | contesting | Pivoting post-COVID into oncology and rare disease, competing on menu breadth per 2026 analysis |
Questions people ask
- Is GeneDx profitable in 2026?
- Not yet on a GAAP basis. GeneDx posted a Q1 2026 GAAP net loss of $63.3M (adjusted loss $8.2M) and cut full-year 2026 guidance about 12%, from $540-555M to $475-490M, on May 4, 2026. Management targets a return to profitability in Q3 2026, but that remains unproven.
- Could AI replace GeneDx?
- Unlikely soon. AI tools like GeneDx's own Multiscore (launched March 2025, 83.5% top-10 gene-ranking accuracy) automate variant interpretation, but GeneDx's moat is its proprietary GeneDx Infinity dataset of over 1 million sequenced exomes/genomes plus 25 years of payer and clinical integration, which a standalone AI vendor cannot replicate.
- Who is GeneDx's biggest competitor?
- Natera is the most credible emerging threat, having shipped a competing rare-disease genomic test called Zenith (with MyOme) in 2026 and holding roughly a $21B market cap versus Illumina's ~$13B as of mid-2025. Labcorp and Quest have distribution scale but lack GeneDx's rare-disease bioinformatics depth.
- Who owns GeneDx?
- GeneDx Holdings (Nasdaq: WGS) is publicly traded with no single controlling owner. It emerged from Sema4 Holdings' April 29, 2022 acquisition of GeneDx from OPKO Health for $150M cash plus 80 million shares, alongside a $200M PIPE that included Pfizer as an investor.
- Why did GeneDx stock crash in May 2026?
- GeneDx shares fell about 49% on May 5, 2026, wiping out over $900M in market cap, after management cut full-year 2026 revenue guidance roughly 12% (to $475-490M from $540-555M), citing unfavorable genome-versus-exome reimbursement mix. This triggered securities class actions with an August 3, 2026 lead-plaintiff deadline.
- What happened with GeneDx's Fabric Genomics acquisition?
- GeneDx acquired Fabric Genomics, an AI genomic interpretation company, for up to $33M cash in May 2025 (up to $51M with milestones). By May 2026 the unit had underperformed, and GeneDx recorded a $31.2M impairment, roughly 94% of the cash paid, tied partly to a $2.5M revenue miss.
Timeline
- 2026-06-05Securities class action filed over 49% stock drop and $31.2M Fabric Genomics write-off
- 2026-05-05GeneDx stock falls ~49% in one day, erasing over $900M in market cap
- 2026-05-04Q1 2026 results; FY2026 guidance cut ~12% to $475-490M; GAAP net loss $63.3M
- 2026-03-20Analyst estimates GeneDx holds ~80% share of rare-disease exome/genome testing
- 2025-10-31FDA grants Breakthrough Device Designation to ExomeDx/GenomeDx testing
- 2025-05-07GeneDx completes acquisition of Fabric Genomics for up to $33M cash
- 2025-03-16GeneDx launches Multiscore, AI-powered gene-ranking tool
- 2024-10GeneDx reports its first profitable quarter
- 2023-10-31GeneDx cuts 10% of staff, launches $40M cost plan, secures $75M debt facility
- 2022-04-29Sema4 completes acquisition of GeneDx from OPKO Health for ~$322M upfront
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- GeneDx Reports First Quarter 2026 Financial Results (2026-05-04)
- GeneDx (WGS) Q1 2026 Earnings Transcript (2026-05-04)
- GeneDx Holdings (WGS) 49% Drop Triggers Investor Scrutiny (2026-05-28)
- Playing the Long Game: At ACMG, Firms Tout Long-Read Offerings (2026-03-20)
- What is Customer Demographics and Target Market of GeneDx (2026-03-18)
- Sema4 Announces the Completion of the GeneDx Acquisition (2022-05-02)
- GeneDx Lays off 10 Percent of Staff... (2023-10-31)
- Document (SEC) (2025-05-07)
- GeneDx Holdings (WGS) Faces Securities Class Action... (2026-06-05)
- GeneDx announces AI-powered gene ranker (2025-03-16)
- A Tale of Two Labs (2025-05-26)
- Genedx Holdings Number of Employees 2026 (2026-06-29)